APAC Antacid Market Size & Growth (2022 to 2027):
As per the research report, the Size of the APAC Antacid Market was valued at USD 3.04 billion in 2022 and is estimated to reach USD 3.69 billion by 2027, to reach at a CAGR of 4% during the forecast period 2022 to 2027.
Over-the-counter digestive products are in high demand, reflecting the growth of the global antacid market. In addition, self-medication is on the rise, contributing to the development of over-the-counter digestive products.
The demand for Antacids is likely to increase dramatically as they neutralize acidity. Nonetheless, about one-third of the adult population in the United States suffers from GERD, according to a study by the American Gastroenterological Association published in the International Functional Foundation in February 2017.
Through digital advertisements and campaigns, the counter drugs are becoming more and more popular, generating growth opportunities for the antacids market. There is a growing need to treat gastrointestinal problems worldwide, creating growth opportunities. The ever-increasing geriatric population drives market demand, as acidity issues are more common in the elderly.
Sedentary lifestyles also contribute to several acidity-related issues, positively impacting the market. Poor lifestyle choices involve deskbound jobs, poor sleep quality, and irregular dietary habits, which increase the stomach's acidity level and lead to gastroesophageal reflux disease. The market for antacids is developing due to the rising need for early diagnosis among individuals. Increased focus on releasing high-quality pharmaceuticals and a high manufacturing pace substantially impact market demand.
The rise of the antacids industry is aided by rising disposable income in metropolitan regions. In addition, the rising popularity of self-medication is accelerating the market's expansion. The demand for antacids is also being fueled by a growing knowledge of the early indications of gastrointestinal illnesses.
Some side effects, including constipation, laxative effect, and allergic responses, will likely slow down the global antacids market's growth pace. Furthermore, individuals with specific medical conditions are more susceptible to adverse effects. For example, people with heart disease are also likely to experience problems due to the high sodium content in antacids. The market's growth is being stifled as a result of this.
This research report on the APAC Antacid Market has been segmented and sub-segmented into the following categories.
By Drug Class:
By Formulation Type:
By Distribution Channel:
By Disease Indications:
Geographically, the Asia Pacific is predicted to be the most significant and fastest-growing regional market over the forecast period. Antacids are commonly used to treat symptoms like excessive heartburn, sore stomach, acid reflux, and stomach discomfort. The Asia Pacific market for medicine delivery services consists of China, India, Japan, South Korea, Australia, and the APAC region.
The China Antacid market and Indian Antacid market are expected to be the fastest-growing markets over the forecast period. Japan, Australia, and South Korea are the following countries in line. Due to enormous unmet patient demands, the availability of effective treatment options, more disposable income, and consumer knowledge of these items' availability.
These nations are also likely to play an essential role in the APAC Antacid market in the coming years. It is related to the region's aging population, rapid urbanization and industrialization, rising disposable income, excellent governmental and private sector R&D investment, and increased consumer awareness. According to Asian Development Bank forecasts, Asia's population of individuals aged 60 and more will double by 2050. All reports suggest a steady growth in APAC Antacid Market.
KEY MARKET PLAYERS
Notable companies dominating in the Asia Pacific Antacid Market profiled in this report are Sun Pharma, Digene (Abbott India), Pudin Hara (Dabur), and GlaxoSmithKline plc, Abbott Laboratories, Pfizer, Inc, Gelusil (Pfizer).,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com